JHL Becomes Eden And Announces Denosumab Progress
Offers Phase I And III Updates On Biosimilar Rival To Amgen’s Prolia
Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.
